Literature DB >> 10682075

Prevalence of gastroesophageal reflux disease in peritoneal dialysis and hemodialysis patients.

J E Anderson1, K B Yim, M D Crowell.   

Abstract

The prevalence of gastrointestinal reflux disease (GERD) in hemodialysis (HD) and peritoneal dialysis (PD) patients was assessed at a single center with a self-administered questionnaire previously used in a general population. It defines (GERD as the presence of heartburn or acid regurgitation, or both. Risk factors for GERD and GERD-associated symptoms were also evaluated. In the studied population, 29.7% of patients had frequent GERD (heartburn, acid regurgitation, or both symptoms weekly). Frequent GERD was reported by 44.7% of PD patients versus the 18.9% reported by HD patients and the 19.8% reported by the general population. PD and HD patients had similar GERD severity scores [2.3 +/- 0.7 vs 1.9 +/- 0.8, mean +/- standard deviation (SD)]. PD and HD patients reported atypical GERD symptoms at rates similar to those reported by the general population, but having GERD made some atypical GERD symptoms more likely (p < 0.05, Fisher's exact test). In a logistic model, age < 60 [odds ratio (OR) 5.6, confidence interval (CI) 1.5-21.3], smoking (OR 4.7, CI 1.3-16.9), and body mass index > or = 27 (OR 3.9, CI 1.2-13.0) predicted GERD. Sex, race, diabetes, PD, non steroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers, and coffee and alcohol use did not. GERD is more common in PD patients than in HD patients or in the general population. It is not clear whether PD per se is a risk factor for GERD.

Entities:  

Mesh:

Year:  1999        PMID: 10682075

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  7 in total

1.  Gastrointestinal symptoms in patients undergoing peritoneal dialysis: multivariate analysis of correlated factors.

Authors:  Rui Dong; Zhi-Yong Guo
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Collagenous Colitis Associated with Rabeprazole in a Peritoneal Dialysis Patient.

Authors:  Masaru Murasawa; Tsutomu Sakurada; Daisuke Oishi; Tomo Suzuki; Naoto Tominaga; Hiroo Kawarazaki; Sayuri Shirai; Yugo Shibagaki; Kenjiro Kimura
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

3.  Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.

Authors:  Tamehachi Namikoshi; Kazuhiro Harada; Hidekazu Hatta; Takehiko Tokura; Yoshiyuki Oshiro; Tetsuichi Nishizaki; Takahiro Obata; Masahiro Mori; Takaaki Fueki; Sohachi Fujimoto; Yoshisuke Haruna; Atsunori Kuwabara; Daisuke Yorimitsu; Chieko Ihoriya; Hiroyuki Kadoya; Seiji Itano; Yasuo Fujimoto; Norio Komai; Tamaki Sasaki; Naoki Kashihara
Journal:  Clin Exp Nephrol       Date:  2015-05-31       Impact factor: 2.801

4.  Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis.

Authors:  Rui Dong; Zhi-Yong Guo; Jia-Rong Ding; Yang-Yang Zhou; Hao Wu
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 5.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

6.  Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Che Lee; Shih-Yuan Hung; Hsi-Hao Wang; Hao-Kuang Wang; Chi-Wei Lin; Min-Yu Chang; Li-Chun Ho; Yi-Ting Chen; Ching-Fang Wu; Ho-Ching Chen; Wei-Ming Wang; Junne-Ming Sung; Yuan-Yow Chiou; Sheng-Hsiang Lin
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

7.  Comparison of endoscopic and pathological findings of the upper gastrointestinal tract in transplant candidate patients undergoing hemodialysis or peritoneal dialysis treatment: a review of literature.

Authors:  Mehmet Usta; Alparslan Ersoy; Yavuz Ayar; Gökhan Ocakoğlu; Bilgehan Yuzbasioglu; Emrullah Düzgün Erdem; Omer Erdogan
Journal:  BMC Nephrol       Date:  2020-10-22       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.